Prediction of Response to Cisplatin-Based Neoadjuvant Chemotherapy of Muscle-Invasive Bladder Cancer Patients by Molecular Subtyping including KRT and FGFR Target Gene Assessment.

导出 OA

翻译打印收藏纠错

第一作者： Thorsten H,Ecke

第一单位： Department of Urology, Helios Hospital Bad Saarow, 15526 Bad Saarow, Germany.

作者： Thorsten H,Ecke ^[1] ; Paula Carolin,Voß ^[2] ; Thorsten,Schlomm ^[2] ; Anja,Rabien ^[2] ; Frank,Friedersdorff ^[2] ; Dimitri,Barski ^[2] ; Thomas,Otto ^[3] ; Michael,Waldner ^[4] ; Elke,Veltrup ^[4] ; Friederike,Linden ^[5] ; Roland,Hake ^[6] ; Sebastian,Eidt ^[6] ; Jenny,Roggisch ^[7] ; Axel,Heidenreich ^[7] ; Constantin,Rieger ^[8] ; Lucas,Kastner ^[9] ; Steffen,Hallmann ^[9] ; Stefan,Koch ^[9] ; Ralph M,Wirtz ^[1]

作者单位： Department of Urology, Helios Hospital Bad Saarow, 15526 Bad Saarow, Germany. ^[1] Department of Urology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany. ^[2] Department of Urology, Evangelisches Krankenhaus Königin Elisabeth Herzberge, 10365 Berlin, Germany. ^[3] Department of Urology, Rheinlandklinikum, 41464 Neuss, Germany. ^[4] Department of Urology, St. Elisabeth Hospital, 50935 Cologne, Germany. ^[5] STRATIFYER Molecular Pathology GmbH, 50935 Cologne, Germany. ^[6] Institute of Pathology, St. Elisabeth Hospital, 50935 Cologne, Germany. ^[7] Institute of Pathology, Helios Hospital, 15526 Bad Saarow, Germany. ^[8] Department of Urology, Universitäsklinikum Köln, 50937 Cologne, Germany. ^[9] Brandenburg Medical School, 16816 Neuruppin, Germany. ^[10]

关键词 FGFR1 FGFR3 KRT20 KRT5 bladder cancer neoadjuvant chemotherapy